BFM
NVO

Boothbay Fund Management’s Novo Nordisk NVO Stock Holding History

Boothbay Fund Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,900
Closed -$758K – 1769
2024
Q1 		$758K Buy
+5,900
New +$702K 0.01% 852

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Boothbay Fund Management's NVO Position: Q1 2026 in Review

Boothbay Fund Management increased its Novo Nordisk (NVO) stake by 40% in Q1 2026, buying an estimated $383K and bringing the position to 28,120 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #930.

Boothbay Fund Management first reported a position in NVO in Q1 2020 and has held it in 20 quarters since. The position peaked at $8.28M in Q2 2022. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Boothbay Fund Management held 28,120 shares of Novo Nordisk worth $1.03M as of Q1 2026.
  • Boothbay Fund Management bought 8,077 Novo Nordisk shares in Q1 2026, an estimated $383K.
  • Novo Nordisk made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #930 holding.
  • Boothbay Fund Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 20 quarters since.
  • Boothbay Fund Management's Novo Nordisk position peaked at $8.28M in Q2 2022.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.